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Summary A cytogenetic study was performed in 27 patients suspected of t-MDS or t-ANLL. In 12 patients
the diagnosis of t-MDS or t-ANLL was confirmed by morphological, cytochemical and immunophenotypical
analysis. The cases were classified as RA (one), RAEB (four), CMML (two), ANLL (five). They had received
chemotherapy and/or RT for Hodgkin's disease (eight cases), solid tumours (three cases) and multiple
myeloma (one case). Clonal chromosome abnormalities were found in bone marrow or peripheral blood cells
in all the 12 cases. Five patients had a clonal abnormality of chromosome no. 5 (monosomy, deletions,
translocation and inversion of 5q). The critical region on chromosome no. 5 comprised bands ql2-q34.
Monosomy and deletion of chromosome 7q was observed in the other two patients. In the six remaining
patients various karyotypic patterns were observed including a t(4;11) (q21;q23) in one case, monosomies (four
cases) and trisomies (one case) of different chromosomes. In the other 15 cases, the presence of a normal
karyotype together with the morphological and immunophenotypical characterisation was consistent with a
diagnosis of non-neoplastic specimens.
Acute non-lymphocytic leukaemia and myelodysplastic syn-
drome represent severe long-term diseases following chemo/
radiotherapeutic regimens for a previous tumour (Zarrabi &
Rosner, 1979; Valagussa et al., 1980; Anderson et al., 1981;
Gomez et al., 1982; Pedersen-Bjergaard & Larsen, 1982;
Pedersen-Bjergaard et al., 1987). At the cytogenetic level the
occurrence of rearranged karyotypes in bone marrow and
peripheral blood cells of these patients has been consistently
reported; in particular, chromosomes 5 and 7 have been
shown to be significantly affected (Rowley et al., 1981;
Sandberg et al., 1982; Pedersen-Bjergaard et al., 1984,
1988; Pedersen-Bjergaard & Philip, 1987; Le Beau et al.,
1986a; Iurlo et al., 1988). Complete losses or deletions
of the long arm of these chromosomes have been observed
and the consequent loss of gene function has been
hypothesised to be crucial in the pathogenesis of these pre-
neoplastic and overtly neoplastic forms (Le Beau et al.,
1986a, b).
Here we present the cytogenetic findings in 12 patients who
developed therapy related myelodysplastic syndrome (t-
MDS) or acute non-lymphocytic leukaemia (t-ANLL). The
patients received combined treatment (chemo/radiotherapy)
for Hodgkin's disease (HD) (seven cases), solid tumours (two
cases) and multiple myeloma (one case). Two patients (one
with HD and one with a solid tumour) were treated with RT
alone. The purpose of this study was a further characterisa-
tion of the chromosome changes in these syndromes which
could be useful to address molecular investigations to
chromosomal regions specifically rearranged.
Materials and methods
We investigated 27 adult patients with a previous history
of chemo and/or radiotherapy for malignancy, and whose
clinical and peripheral blood findings were suggestive of a
diagnosis of t-MDS and/or t-ANLL. In 12 of these, the bone
marrow examination confirmed the provisional diagnosis.
The patients were classified according to the FAB criteria on
the basis of morphological, cytochemical and cell markers
analyses, as previously described (Orazi et al., 1988).
In the other 15 cases the bone marrow morphology was
consistent with non-myelodysplastic transient cytopenias and
the peripheral blood count reverted to normality in subse-
quent examinations. The cytogenetic analysis was performed
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on bone marrow and/or peripheral blood samples using
24-48 h unstimulated cultures. Chromosome preparations
were carried out according to standard methods (Yunis,
1981). At least 10 metaphases were analysed by the G-
banding technique and chromosome abnormalities were de-
scribed in accordance with the International System for
Human Cytogenetic Nomenclature (ISCN, 1985).
Results
Table I summarises the clinical data relative to the 12
patients. In eight cases the first tumour was diagnosed as HD
whereas the other four patients have previously suffered
multiple myeloma, carcinoma of the breast, basalioma and
osteosarcoma, respectively. Treatment consisted of combined
radiotherapy (RT) and chemotherapy except cases 5 and 12,
which received only RT. The chemotherapeutic drugs always
included alkylating agents.
The mean time elapsing between the beginning of treat-
ment for primary tumour and the diagnosis of the secondary
disorder was 7.8 years (range 1-12.7 years). Of the six
patients who developed t-MDS, one was classified as RA
according to the FAB classification, three as RAEB and two
as CMML. The remaining six patients had t-ANLL of M2
FAB subtype (two cases), M5 (three cases) and AUL (one
case); in two patients (nos. 11 and 12) the t-ANLL M2 was
preceded by an MDS, diagnosed on bone marrow examina-
tion, with a duration of 22 and 2 months, respectively.
In two other cases (nos 8 and 9) peripheral blood anom-
alies preceding the onset of leukaemia and consistent with a
MDS phase were observed. However, no bone marrow exam-
inations were performed at this stage. In case nos 7 and 10,
no peripheral blood disturbances were present. Mean survival
time from the diagnosis of the secondary disorder was 6.4
months (range 1-18 months), with four patients still alive.
All the 15 patients who did not receive diagnosis of t-MDS
or t-ANLL showed normal karyotype. The results of the
cytogenetic analyses in the 12 patients with t-MDS or t-ANLL
are shown in Table II. All of them presented aneuploid
kayrotype with tendency to hypodiploidy. Abnormalities of
chromosome 5 were observed in five patients with the
complete loss of one chromosome 5 in case no. 2, a del(5)
(q12q34) in cases nos 3 and 4, a t(5;20) (ql2;ql3) in case
no. 11 and an inv5(pl5.lql2) in case no. 12. Monosomy of
chromosome 7 and del(7) (q22) was observed in cases nos 4
and 8, respectively. In patient no. 4, 50% of the cells
analysed showed both a del(5) (ql2q34) and monosomy 7.
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Table I Clinical data
t-MDS
Interval t-ANLL Survival
Case Age/sex Ist tumour Therapy (months) (FAB subtype) (months)
1 36 F HD RT, MOPP, ABVD 126 RA 19 (a)
2 59 M HD RT, MOPP 102 RAEB 5 (d)
3 63 M multiple RT, PRED/ADM 56 RAEB I (d)
myeloma VCR/CTX, CCNU
4 67 F ca breast RT, ADM, MMC 93 RAEB 10 (d)
5 70 M basalioma RT 60 CMML 28 (a)
6 60 M HD RT, MOPP, ABVD 65 CMML 12 (d)
7 32 M HD RT, MOPP 153 AUL 3 (d)
8 56 F HD RT, MOPP, ABVD, 42 RAEBt/ANLL M5 3 (d)
CEP, leukeran
9 32 F HD RT, MOPP 146 RAEBt/ANLL M5 2 (d)
10 17 M osteosarcoma ADR, BLEO, CTX, 31 RAEBt/ANLL M5 24 (a)
actinomycin D
I1 66 F HD RT, MOPP 240 RAEBt/ANLL M2 25 (a)
12 43 M HD RT 9 RAEBt/ANLL M2 19 (d)
M, male; F, female; d, died; a, alive; HD, Hodgkin's disease; RT, radiotherapy; MOPP, mechloretamina,
vincristine, procarbazine, prednisone; ABVD, doxorubicin, bleomycin, vinblastine, decarbazine; PRED, pred-
nisone; ADM, adriamycin; VCR, vincristine; CTX, cyclophosphamide; BLEO, bleomycin; CEP, CCNU,
etoposide, prednimustine; CCNU, lomustine.
Table II Cytogenetic data
Percentage
Case Specimen No. ofmetaphases abnormal Karyotype
I BM 21 19 46xx, -12, + mar
2 BM 10 50 46xx, -5, + mar
3 BM 9 100 46xy,del(5)(q12q34)
4 BM 11 100 47xx,del(5)(qI2q34), + mar(50%)
46xx,same, -7(50%)
5 BM 11 90 45xy,-22
6 PBL 19 68 45xy,-21
7 PBL 15 66 46xy,t(4;11(q21;q23)
8 BM 10 100 46xx,del(7)(q22) (80%)
45x,same, - x (20%)
9 BM 10 45 46x,-x, + mar
10 BM 15 100 48xy,dup(1q)(ql -*q12), + 3, + 9
11 BM 31 87 46xx,inv dup(3q)(q21-*q26),
t(5;20)(q12;q13)
12 BM 15 100 46xy,inv(5)(p15.1ql2),t(9;14)
(p23;q21),inv(16)(p13q22)
Partial karyotypes from patients with abnormalities of chro-
mosome 5 and 7 are shown in Figure 1.
Monosomies of chromosomes 12, 21, 22 and X were ob-
served in the other four cases, and in two of them the
monosomy was associated with the presence of a small
marker chromosome of unidentified origin. Case no. 10 pre-
sented trisomies of chromosome 3 and 6 and a marked
heteromorphism between the two chromosomes 1. In case
no. 7 a t(4;11) (q21;q23) was present as the only change. The
immunological phenotype of this case was Tdt-, CD7-,
HLA-DR+, CDl9+, CD33-, suggesting an early pro-
genitor cell bearing some lymphoid-associated antigens
together with evidence of early monocytic differentiation
(Orazi et al., 1988).
Discussion
In this study chromosome aberrations were observed in
100% of the patients with t-MDS and t-ANLL who had
received single (RT) or combined (RT + alkylating agents)
treatment for a previous neoplastic disease.
In our cases chromosome 5 was the most frequently re-
arranged and the abnormalities consisted in monosomy (case
no. 2), delS(ql2q34) (cases nos 3 and 4), and t(5;20)
(ql2;ql3) with a derivative Sq - chromosome (case no. 11).
Whereas monosomy and partial deletion of chromosome 5
has been frequently observed (Le Beau et al., 1986a; Pedersen-
Bjergaard & Philip, 1987; Pedersen-Bjergaard et al., 1988;
Zaccaria et al., 1987; Iurlo et al., 1988), the rearrangement
observed in case no. 11 is, to our knowledge, the first
cytogenetic evidence of a translocation of the deleted
sequence from chromosome 5q to another chromosome. In
addition, an inv(5) (pl5.1ql2) was present in case no. 12
leading to an intrachromosome relocation of the region q12-
q34 of chromosome 5. Thus, this region of chromosome 5
could represent a target for mutagenic agents that might
cause either complete or partial deletion of genes on 5q, or
inter/intra-chromosome relocation of the region ql2-q34.
These observations lend support to the hypothesis that fol-
lowing the loss or deletion of chromosome 5q, critical gene(s)
could be inactivated, resulting in alterations of cell growth
control (Le Beau et al., 1986a, b). In addition a number of
genes coding for proteins involved in haematopoiesis are also
localised on chromosome 5 (q21-q33) (GM-CSF, CSF-1,
FMS, IL-3, PDGFR, ECGF, IL-5), and therefore could be
directly deregulated by the observed chromosome rearrange-
ments. The latter possibility is consistent with the karyotypes
observed in our cases nos 11 and 12, which presented a
translocation of the region ql2-q34 and a pericentric inver-
sion p15-qI2 of chromosome 5, respectively, suggesting that
also other chromosomal rearrangements could lead to an
altered regulatory control due to the relocation of genes
belonging to chromosome 5(ql2-q34). In particular, the con-
sistency of the breakpoints on 5ql2 points to this region as
being of critical importance. The same hypothesis has been
suggested by Mecucci et al. (1987), who reported two cases of
paracentric inversion of the long arm of chromosome 5 in
secondary myelodysplastic syndromes.
The data relative to the prognostic value of cytogenetic
findings in secondary haematological disorders are still con-
troversial. In fact, Pedersen-Bjergaard and Philip (1987) andCYTOGENETICS IN t-MDS AND t-ANLL 427
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Figure 1 Partial karyotypes from patients with abnormalities of chromosomes nos 5 and 7.
lurlo et al. (1988) found a significantly shorter survival in
patients showing multiple chromosome aberrations as com-
pared to patients with a single karyotypic alteration, includ-
ing monosomy 7. In contrast, Le Beau et al. (1986a), in a
large cytogenetic study of 63 patients with t-MDS and t-
ANLL, did not find any significant difference in the clinical
course and survival time when patients were grouped accord-
ing to the complexity of their karyotype (abnormalities of
chromosomes 5 and/or 7 alone, or with additional re-
arrangements). In our cases the majority of the rearranged
karyotypes displayed simple chromosome changes, patient 12
being the only one with a complex karyotype. The survival
time was poor in patients with abnormalities of chromosome
5 and/or 7 and in patients presenting other changes (mean
values 7.2 and 5 months, respectively). However, only one of
the six patients with abnormalities ofchromosome 5 and/or 7
was alive, whereas three of the six patients with changes not
involving these chromosomes were still alive. Thus, although
the total number of patients was too small for a meaningful
statistical comparison, patients with abnormalities of
chromosomes 5 and/or 7 had a tendency towards a worse
prognosis. It is noteworthy that the only patient alive in this
group ofpatients (no. I1) showed a balanced translocation of
5q instead of the complete or partial deletion of this
chromosome, suggesting that only the deletion of 5q and the
consequent loss of critical gene(s) on 5q may be related to a
worse prognosis. In addition, the other patient showing a
balanced rearrangement of chromosome 5, an inv(S)
(p15.1q12), without any visible loss of material on Sq
(no. 12), died after the longest survival time (18 months)
observed in the group of patients with abnormalities of
chromosome 5 and/or 7.
In conclusion, the present results confirm that abnor-
malities ofchromosome 5 and/or 7 are frequently observed in
secondary haematological disorders and could be of diagnos-
tic and prognostic value. Further molecular analysis of the
involved chromosomal regions will clarify their role in the
pathogenesis of secondary haematological disorders.
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